on a mobile?
 
vTap
    Loading...
 
 
Video
1575
...sion to sell its Irish plant, reports CNBC-TV18. "The Irish plant sell-off is an effort to discourage Sun from acquiring Taro. We are vigorously disputing the termination of merger agreement by ...
5 months ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
CNBC-TV18
Mergers and acquisitions
CNBC
Go to Feed to see what's new!
share
keep
 
 
5 months ago
NDTV.COM
Keep this video in the "Saved" list
Go to Feed to see what's new!
share
keep
 
 
2325
...eal are seen coming from the market experts. The deal is seen as the first generics-proprietary partnership in global pharma. Udayan Mukherjee, CNBC-TV18 explains that Ranbaxy is the largest ...
5 months ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
Udayan Mukherjee
CNBC-TV18
Daiichi Sankyo Co.
CNBC
Go to Feed to see what's new!
share
keep
 
 
9270
...va's multiple sclerosis drug Copaxone, which has US sales of over USD 2 billion, reports CNBC-TV18. The drug is marketed by Sanofi Aventis. Natco has tied up with a US generic company Mylan for ...
5 months ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
Glatiramer acetate
Sanofi-Aventis
Pharmaceutical company
Teva Pharmaceutical Industries
CNBC-TV18
Multiple sclerosis
United States dollar
CNBC
Go to Feed to see what's new!
share
keep
 
 
Templeton Asset Management Ltd has challenged Sun Pharma's acquisition of Taro Pharma, reports CNBC-TV18.
a year ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
CNBC-TV18
Mergers and acquisitions
Go to Feed to see what's new!
share
keep
 
 
More Videos
 
Keep this video in the "Saved" list
Go to Feed to see what's new!
share
keep
 
 
 
 
25875
Sun Pharma said Taro is not entitled to terminate the merger, reports CNBC-TV18, quoting sources. According to the Indian pharma major, the merger offer of USD 10.25 per share is in the best interest of shareholders. It will consider all options, inc...
5 months ago
moneycontrol.com
Keep this video in the "Saved" list
Now, put vTap to work for you!
Let us keep you up to date with new videos related to:
CNBC-TV18
CNBC
Go to Feed to see what's new!
share
keep
 
 

Corporate Home Corporate Home News FAQ About Contact Forums
Privacy Policy and Terms of Use